icon-    folder.gif   Conference Reports for NATAP  
 
  XIX International AIDS Conference
July 22-27, 2012
Washington, DC
Back grey_arrow_rt.gif
 
 
 
Efficacy and Safety Results from a Randomized, Double-Blind, Active-Controlled Trial of Elvitegravir (Once-Daily) vs. Raltegravir (Twice-Daily) in Treatment-Experienced HIV-Infected Patients: Long Term 96-Week Data
 
 
  Reported by Jules Levin
XIX International AIDS Conference
July 24, 2012
 
Richard Elion1, Jean-Michel Molina2, Jose-Ramon Arribas-Lopez3, David A Cooper4, Franco Maggiolo5, Edmund Wilkins6, Brian Conway7, Ya-Pei Liu8, Lijie Zhong8, Nicolas Margot8, Javier Szwarcberg8, Martin S Rhee8, Andrew K Cheng8
 
1Whitman-Walker Health, Washington DC, United States, 2Hopital Saint Louis, Service des Maladies infectieuses, Paris, France, 3Hospital Universitario La Paz, Servicio de Medicina Interna, Unidad VIH, Madrid, Spain, 4Kirby Institute, University of New South Wales, Sydney, Australia, 5Ospedali Riuniti di Bergamo, Bergamo, Italy, 6North Manchester General Hospital, Manchester, United Kingdom, 7Vancouver ID Research & Care Centre, Vancouver, Canada, 8Gilead Sciences, Foster City, United States

IAC1.gif

IAC2.gif

IAC3.gif

IAC4.gif

IAC5.gif

IAC6.gif

IAC7.gif